Benevento

Researchers are evaluating which rescue bowel preparation works best for adults who need a repeat colonoscopy after an earlier bowel preparation did not clean the bowel well enough. The study aims to find out which preparation helps more participants achieve adequate bowel cleansing, which one cleans different colon parts better, and which is better tolerated by participants. This trial compares three rescue bowel preparation regimens to answer these questions. Participants will be randomly assigned to one of three groups before their repeat colonoscopy one group will take 4 liters of polyethylene glycol PEG plus 12 mg of bisacodyl another group will take 1 liter of PEG plus ascorbic acid and 10 mg of bisacodyl and the third group will take 2 liters of PEG plus extra PEG over the three days before the procedure. Each preparation is given as a rescue method after a previous inadequate bowel cleansing. During the study, participants will undergo the repeat colonoscopy where researchers will assess bowel cleansing quality using the Boston Bowel Preparation Scale in different colon sections. Participants will also rate their satisfaction with their bowel preparation. Researchers will monitor polyp detection and bowel preparation adequacy on the day of colonoscopy. The study is sponsored by Ospedale San Pio and runs until June 2026.

Researchers are conducting a multicenter, observational study in Italy to collect detailed information on patients with bone metastases. The study aims to establish a national database to better understand clinical and biological factors related to primary tumors and their bone metastases. This research will also evaluate the impact of treatments and care pathways on skeletal events over a period of up to 15 years. Patients with bone metastases from solid tumors will be enrolled in this study and registered in a specialized online database. Each participant will be followed from enrollment until death or until they stop follow-up for other reasons. The study does not involve any experimental treatments but collects comprehensive data on patients conditions and care. Participants will provide informed consent and their medical data will be regularly recorded and analyzed. The study monitors clinical outcomes, skeletal-related events, and the efficiency of treatment pathways. Data collection will continue for up to 15 years, providing long-term insights into bone metastases and patient management.

Researchers are conducting an international, multicenter, prospective observational registry to study patients with X-Linked Hypophosphatemia XLH. This registry aims to collect detailed data on the natural history, treatment patterns, progression, and long-term outcomes of XLH in both adults and children. The study includes patients regardless of whether they are currently receiving treatment for XLH. Participants will be enrolled in a non-interventional setting without any additional treatments or procedures beyond their standard clinical care. Data will be collected retrospectively and prospectively using a web-based system. Physicians will update patient information during routine visits, with reminders to update data approximately every 12 months. Some sites may also participate in a post-authorization safety study PASS to monitor treatment-related adverse events. Participants will provide informed consent or assent according to age and national guidelines. The study team will collect baseline and ongoing clinical information, including treatment details and adverse events, over a period extending to 10 years. No fixed follow-up schedule is required, but data updates align with patients usual healthcare visits. Researchers will review adverse events related to treatment as a primary outcome measure throughout the study period.

Oligometastatic breast cancer occurs when breast cancer has spread to a limited number of other body sites. Patients with this condition may live longer than those with more widespread metastases. Researchers are investigating whether adding local treatments like stereotactic body radiotherapy SBRT, a non-invasive radiation therapy delivering high doses in a few sessions, can improve disease control and survival in these patients. This study is a multicenter retrospective analysis aiming to better understand SBRTs role in this setting. The study focuses on patients who have received SBRT to their oligometastatic sites, delivering a minimum radiation dose of 50 Gy EQD2 in up to 12 sessions, following the Oligocare definition. This local treatment is considered alongside standard systemic therapies like chemotherapy or hormonal therapy. The study collects data from treatments performed between January 2010 and December 2023 to evaluate outcomes. Participants data will be reviewed retrospectively to measure progression-free survival as the primary outcome. Secondary outcomes include local control of treated sites, overall survival, and acute or late radiation-related toxicities. The study covers treatments applied outside the brain and aims to provide insights into the safety and effectiveness of SBRT in managing oligometastatic breast cancer. The overall participation involves analysis of existing patient records from multiple centers up to the end of 2023.

Researchers are investigating a new approach to heart stress imaging called the ABCDE protocol, developed from the previous SE 2020 study. This international, multicenter study focuses on various heart conditions including coronary artery disease, heart failure with preserved ejection fraction, hypertrophic cardiomyopathy, valvular heart disease, and complications after chest radiotherapy, chemotherapy, or COVID-19. The study aims to enroll over 10,000 patients from multiple countries and labs, following them for at least five years to improve stress echocardiography as a versatile diagnostic tool. The study uses different types of stress echocardiography, including physical, pharmacologic, and pacing stress tests, with a standardized ABCDE protocol to assess heart function. Participating labs will use AI software and ultrasound enhancing agents to support uniform testing and data collection. The study also includes specialized projects targeting specific conditions such as repaired Tetralogy of Fallot, heart donors, and coronary vasospasm, all integrated under the ABCDE-SE platform. Participants will undergo regular clinical follow-ups with detailed data collection on demographics, lifestyle, imaging, and cardiovascular events. The study measures important outcomes like all-cause death, cardiac death, and cancer diagnosis over five years. Data on environmental factors and medical radiation exposure will also be analyzed. This approach aims to provide strong evidence for the use of stress echocardiography as a low-cost, radiation-free, and accessible test for patients worldwide.

This research focuses on cancer patients registered in the ROC platform, a multicenter database in the Campania region. It aims to gather and analyze data retrospectively and prospectively to improve understanding of cancer patient outcomes and care. The study seeks to monitor the ROC platforms performance and provide insights into cancer epidemiology, treatment, and healthcare management in this region, which has worse oncological outcomes compared to other Italian areas. Participants come from two groups those already recorded in the ROC platform since its activation in November 2018 until the studys start, and new patients entering the platform after ethical approval. Data collection covers a wide range of information, including tumor incidence, treatment strategies, diagnostic activities, and adherence to clinical guidelines. These data are collected continuously and analyzed at set intervals over several years. During the study, researchers will evaluate many outcomes such as tumor incidence and prevalence, timing between diagnostic and therapeutic activities, patient quality of life, costs related to care inefficiencies, and patient satisfaction. Assessments will occur regularly up to five years or longer, depending on the measure. This ongoing monitoring aims to provide comprehensive knowledge to improve cancer care and decision-making for patients in the Campania region.

This observational study focuses on patients with head and neck squamous cell carcinoma HNSCC undergoing radical or adjuvant radiation therapy. Researchers aim to understand how vitamin D levels vary over time in these patients and how these levels relate to therapy side effects, disease outcomes, and toxicity. The study addresses gaps in current knowledge by prospectively evaluating vitamin Ds potential impact on treatment results and patient prognosis across multiple centers. Participants will be patients with confirmed non-metastatic locally advanced HNSCC who are candidates for bilateral neck irradiation as part of their radiation therapy. The study does not involve experimental treatments but follows patients as per standard clinical practice. Vitamin D levels will be measured at diagnosis and at various time points, including 4 and 7 weeks, to observe variations and possible links with treatment toxicity and disease response. During the study, researchers will collect data on vitamin D levels alongside monitoring radiotherapy side effects, treatment responses, relapse-free survival, and overall survival up to two years. Follow-up aligns with routine clinical care, and no additional interventions are given. The primary outcome is vitamin D variation at 7 weeks, with secondary outcomes including toxicity, response, and survival measures. Participants involvement mainly consists of blood tests and clinical evaluations conducted during their regular treatment visits.